J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst Zain Ebrahim maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Ebrahim is ranked #10728 out of 12068 analysts.
In addition to J.P. Morgan, GlaxoSmithKline also received a Sell from Barclays’s James Gordon CFA in a report issued on March 24. However, on March 26, Berenberg Bank reiterated a Hold rating on GlaxoSmithKline (LSE: GSK).
Based on GlaxoSmithKline’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of p8.62 billion and a net profit of p636 million. In comparison, last year the company earned a revenue of p8.12 billion and had a net profit of p414 million
Based on the recent corporate insider activity of 323 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GSK in relation to earlier this year.
Read More on GB:GSK:
Disclaimer & DisclosureReport an Issue
- GSK announces EMA accepted for review the MAA for use of bepirovirsen
- GSK expands share buyback, lifts treasury stake to 6.28%
- GSK’s Hepatitis B Drug Bepirovirsen Accepted for EMA Review After Positive Phase III Data
- GSK Continues Share Buyback, Lifts Treasury Holdings to 6.27% of Voting Rights
- GSK Reports Routine ADS Acquisition by U.S. President Martinez-Davis
